AI
Wednesday, May 21, 2008 10:58:50 AM
- from Rolf Brekken's September 2007 "Bavituximab preclinical studies" presentation, consisting of collaborative research into Bavituximab's immune-modulating MOA at Duke University & SRI.
One of the most important graphs I've ever seen, with implications for treating tumors, enveloped viruses, malaria, trypanosoma, toxoplasma, leishmania..
j
full "Bavituximab preclinical studies" presentation:
http://presentations.cancerconferences.com/7th_monoclonal/files/2007_0817/ws02_brekken.pdf
---------
j
Recent CDMO News
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • SMX • Oct 3, 2024 7:00 AM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM
